n an anticlimactic finish to an embarrassing scandal, the Japanese government has scolded Bayer (BAYRY) for improper promotional activities and, at the same time, ordered the company to bolster its procedures for reporting side effects.

The health ministry issued a verbal guidance after finding Bayer employees “inappropriately” accessed patient data as part of a plan to promote the Xarelto blood thinner. The data was taken from surveys in medical journal papers when Xarelto was launched in 2012 and a former Bayer sales rep claimed he was instructed to gather the data from dozens of patients about dosing and related health matters.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Pharmaceutical production
Drug Pricing

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.